← Back to dossier
Patient handout

Acute HF — RV-predominant decompensated HF

PRODUCTION

1. Your condition

This handout is for acute hf — rv-predominant decompensated hf. Your care team identified this based on: echo with severe rv dilation + dysfunction (tapse <14, rvfac <25%) + low pcwp → rv-predominant adhf.

Other reasons your team may use this plan: inferior stemi + v4r st elevation + hypotension + clear lungs → rv infarction (goldstein nejm 1990); known pah/ph + acute decompensation (syncope, pre-arrest, lactate rise) → ph crisis; post-pulmonary embolectomy or post-ct-surgery with isolated rv failure.

2. Your medications

Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.

MedicationStarting doseHowWhenWhat it does
normal saline 0.9%250-500 mL IV bolus over 15-30 minIVone bolus then reassessGoldstein NEJM 1990 — RV is preload-dependent; small bolus often improves CO; STOP if CVP rises without CO improvement (over-distention)
dobutamine2.5 µg/kg/min IV titrate to 10 µg/kg/minIVcontinuousInotropic support for RV; less arrhythmogenic at low doses; preferred over isolated LV-MCS in RV failure
milrinone0.125-0.5 µg/kg/min IV (no bolus)IVcontinuousInodilator with pulmonary vasodilation — useful in RV failure with elevated PVR; renal adjustment; avoid if hypotensive (OPTIME-CHF)
norepinephrine0.05 µg/kg/min IV titrate to MAP ≥65IVcontinuousMaintains MAP for coronary perfusion to RV — coronary perfusion = MAP - CVP; SOAP-II PMID 20200382
vasopressin0.03 U/min IVIVcontinuous; not titratedV1-mediated vasoconstriction sparing pulmonary vasculature — preferred second pressor in RV failure with PH
inhaled nitric oxide20-40 ppm inhaledINHcontinuousSelective pulmonary vasodilation reduces RV afterload; ESC 2021 HF Class IIb; wean slowly to avoid rebound PH
inhaled epoprostenol50 ng/kg/min nebulizedINHcontinuousInhaled prostacyclin alternative to iNO; selective pulmonary vasodilation; lower cost than iNO
furosemideCAUTIOUS — 20-40 mg IV ONLY if clearly volume-overloaded (rising CVP without CO improvement)IVas neededOver-diuresis worsens RV preload; use only if clearly congested + monitor CVP + CO closely

Plan: RV-predominant ADHF — preload-dependent, pulmonary vasodilator + dobutamine + AVOID isolated LV-MCS (ESC 2021 HF; Konstantinides 2019 PE)

3. When to call your provider

Contact your care team if any of the following happen:

  • Worsening WHO class → escalate to triple PAH therapy
  • Recurrent RV decompensation → transplant evaluation

4. When to seek emergency care

Call 911 or go to the nearest emergency room right away if you have:

  • RV-predominant cardiogenic shock with persistent lactate ≥4, MAP <65 despite NE + vasopressin + dobutamine + iNO(life-threatening)
  • Known PAH + new syncope/pre-arrest/lactate rise + severely elevated PA pressure on echo(life-threatening)
  • Inferior STEMI + V4R ST elevation + hypotension + clear lungs → RV-MI with shock(life-threatening)
  • Hemodynamically unstable acute PE with RV failure on echo (RV/LV >1.0, septal flattening, low CO)(life-threatening)

5. Follow-up

PAH-specific therapy escalation if PH crisis; cardiac rehab; advanced HF + transplant/LVAD eval if recurrent RV decompensation

6. Sources

Guideline: ESC 2021 HF + 2022 ACC/AHA HF + Konstantinides ESC 2019 PE

  1. pubmed.ncbi.nlm.nih.gov/34447992
  2. pubmed.ncbi.nlm.nih.gov/35363499
  3. pubmed.ncbi.nlm.nih.gov/38264914